Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explores the use of low-dose naltrexone as a novel treatment for lichen planopilaris, but specific results or outcomes are not detailed in the abstract.

This review discusses previously reported cases of drug-associated hidradenitis suppurativa linked to various immunomodulating medications but reports no new clinical results.

This study found that among 17 beta-(N-ureylene-N,N'-disubstituted)-4-azasteroids, those with an N'-phenyl moiety were the most effective inhibitors of human type I 5 alpha-reductase.

This study reports that two oral hormonal agents, dimethandrolone undecanoate and 11β-methylnortestosterone dodecylcarbonate, may effectively suppress hormones to contraceptive levels in men with mild side effects, though longer-term trials are required to confirm their safety and efficacy.

This case study potentially links the use of anabolic steroids to increased severity of COVID-19 in a healthy 28-year-old man, with marked symptom improvement following treatment with proxalutamide.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study found that dutasteride treatment in pregnant mares significantly increased progesterone concentrations but did not alter gestational length or neonatal outcomes.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study found that nanostructured lipid carriers enabled effective follicular delivery and accumulation of anti-hair loss drugs like dutasteride in mice, suggesting potential for reduced dosage frequency.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This article reviews guidelines and medications for treating benign prostatic hyperplasia but presents no new clinical results.

This study found that AR-positive breast cancer cell lines are more sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235 compared to AR-negative cells.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

This study found that early treatment with estradiol or dihydrotestosterone significantly reduced prostate adenocarcinoma development in Lobund-Wistar rats, while later treatments were ineffective.

This study found that among Japanese IBD patients, the NUDT15 p.Arg139Cys variant was significantly associated with thiopurine-induced leukopenia and severe hair loss, suggesting its genotyping is important for predicting these adverse events.

This study found that MK-386 selectively suppressed sebum DHT levels in a dose-dependent manner, suggesting potential use for treating acne.

This study developed a new competitive 5alpha-reductase inhibitor with an IC(50) of 0.84 microM using a novel chemical structure.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

This study found that long-term flutamide treatment reduced hair loss in women with female pattern hair loss, but liver-related dropouts were minimized at a very low dose of 62.5 mg/day.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

This study found that torilin from Torilis japonica fruit extract inhibited 5 alpha-reductase in vitro more effectively than alpha-linolenic acid but less effectively than finasteride.